The present study was designed to characterize transduction of non-human primate brain
and spinal cord with AAV5 viral vector after parenchymal delivery. AAV5-CAG-GFP (1× 10 …

Recombinant adeno-associated virus vectors based on serotype 2 (rAAV2) can direct
transgene expression in the central nervous system (CNS), but it is not known how other …

Adeno-associated virus (AAV) vectors exhibit a number of properties that have made this
vector system an excellent choice for both CNS gene therapy and basic neurobiological …

The capacity of certain adeno-associated virus (AAV) vectors to cross the blood–brain
barrier after intravenous delivery offers a unique opportunity for noninvasive brain delivery …

Effective gene delivery to the central nervous system (CNS) is vital for development of novel
gene therapies for neurological diseases. Adeno-associated virus (AAV) vectors have …

Various regions of the brain have been successfully transduced by recombinant adeno‐
associated virus (rAAV) vectors with no detected toxicity. When using the cytomegalovirus …

Adeno-associated virus (AAV) is a promising vector for central nervous system (CNS) gene
transfer, but a number of issues must be addressed if AAV is to be used for widespread …

Widespread distribution of gene products at clinically relevant levels throughout the CNS
has been challenging. Adeno-associated virus type 9 (AAV9) vector has been reported as a …

The present study was designed to characterize transduction of non-human primate brain
and spinal cord with a modified adeno-associated virus serotype 2, incapable of binding to …

Recombinant adeno-associated viral (rAAV) vectors are frequently used for gene delivery to
the central nervous system and are capable of transducing neurons and glia in vitro. In this …